Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Bio-Techne ( (TECH) ).
On February 4, 2026, Bio-Techne reported second-quarter fiscal 2026 results for the period ended December 31, 2025, with revenue flat year-on-year at $295.9 million but improvements in profitability driven by cost controls and portfolio optimization. GAAP EPS rose to $0.24 from $0.22, while adjusted EPS increased to $0.46 from $0.42, and adjusted operating margin expanded 100 basis points to 31.1%, aided by ongoing productivity initiatives and the divestiture of Exosome Diagnostics, despite an unfavorable product mix. The Protein Sciences segment posted 2% higher reported sales, though organic revenue slipped 1%, and its margin narrowed due to mix effects, whereas the Diagnostics and Spatial Biology segment saw a 4% decline in reported sales but 3% organic growth and a sharp margin improvement to 10.4% as the held-for-sale business and Exosome Diagnostics were removed from results. Management highlighted continued double-digit growth in large pharma, stabilizing demand from U.S. academic customers, and a third consecutive quarter of growth in China/APAC, underscoring a more stable operating environment as the company marks its 50th anniversary and reinforces its positioning in high-value life science and diagnostic applications.
The most recent analyst rating on (TECH) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Bio-Techne stock, see the TECH Stock Forecast page.
Spark’s Take on TECH Stock
According to Spark, TipRanks’ AI Analyst, TECH is a Neutral.
Bio-Techne’s overall stock score is driven by stable financials with low leverage, positive technical momentum, and mixed earnings call insights. However, high valuation and declining revenue growth are significant concerns.
To see Spark’s full report on TECH stock, click here.
More about Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company that provides innovative tools and bioactive reagents to research and clinical diagnostic customers. Its products support investigations into biological processes and disease progression, aid drug discovery, and enable accurate clinical testing and diagnoses. With a portfolio of thousands of products, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and employs about 3,100 people worldwide.
Average Trading Volume: 2,037,683
Technical Sentiment Signal: Buy
Current Market Cap: $10.17B
See more data about TECH stock on TipRanks’ Stock Analysis page.